Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ELTX vs URGN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
URGN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)
URGN Overall Winner
6-Pillar Tally: ELTX 2 – 3 URGN (1 Tie)
Matrix Metrics: ELTX 3 – 7 URGN
As of Nov 20, 2026, UroGen Pharma Ltd. (URGN) is the stronger overall head-to-head candidate over Elicio Therapeutics, Inc. (ELTX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ELTX carries a Unified Composite Score of 53.1/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin), whereas URGN carries 62.7/100 (BUY) at $27.65 (11.1x Forward P/E, -12.4% operating margin).
- Technical & Structure Timing Caution: ELTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.7); meanwhile URGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ELTX vs URGN
ELTX
Elicio Therapeutics, Inc. Common Stock
$1.45
-3.33% 1D
Market Cap
$42.5M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
0.41β · 92% Vol
Unified Composite Score
53.1
HOLD
Tech 72.0
Fund 60.0
Flow 66.0
Mom 54.0
Weinstein Technical Phase
Markdown · Sell / avoid
URGN
Head-to-Head Winner
UroGen Pharma Ltd. Ordinary Shares
$27.65
-12.86% 1D
Market Cap
$1.5B
TTM Revenue
$250M
Forward P/E
11.1x
Beta / 30D Vol
1.24β · 90% Vol
Unified Composite Score
62.7
BUY
Tech 58.0
Fund 59.0
Flow 69.0
Mom 50.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (ELTX 2 – 3 URGN)
1. Valuation Multiples
URGN
Forward P/E
N/M
11.1x
Trailing P/E
N/M
14.6x
PEG Ratio
N/M
N/M
EV / Revenue
N/M
6.6x
2. Growth & Scale
URGN
Revenue Growth (YoY)
+0.0%
+223.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$250M
Market Cap
$42.5M
$1.5B
3. Profitability & Quality
ELTX
Gross Margin
N/A
91.4%
Operating Margin
0.0%
-12.4%
Net Profit Margin
0.0%
-26.3%
Return on Equity (ROE)
-315.3%
-1481.3%
4. Balance Sheet & Cash Flow
ELTX
Cash Generation (TTM)
-$38M
-$132M
Cash Flow Margin
N/A
-52.8%
Net Cash / Leverage
$9.3M Net Cash
$111M Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
URGN
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
76.3% (<1st %ile)
109.4% (10th %ile)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ELTX (3) vs URGN (7)| Institutional Metric | ELTX | URGN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $42.5M | $1.5B | URGN | |
| Trailing P/E Ratio | N/M | 14.6x | URGN | |
| Forward P/E Ratio | N/M | 11.1x | URGN | |
| Revenue Growth (YoY) | +0.0% | +223.9% | URGN | |
| Operating Margin (TTM) | 0.0% | -12.4% | ELTX | |
| Net Profit Margin | 0.0% | -26.3% | ELTX | |
| Return on Equity (ROE) | -315.3% | -1481.3% | ELTX | |
| 52-Week Range Position | 1% ($1–$16) | 32% ($16–$51) | URGN | |
| Beta / 30D Volatility | 0.41β · 92% Vol | 1.24β · 90% Vol | URGN | |
| Unified Institutional Score | 53.1 / 100 (HOLD) | 62.7 / 100 (BUY) | URGN | |
| Trailing 12M Revenue (USD) | N/A | $250M | Scale | |
| Gross Profit Margin (TTM) | N/A | 91.4% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 6.6x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$38M ($9.3M Net Cash) | -$132M ($111M Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
URGN +3.92 pp
3M Horizon
URGN +11.24 pp
6M Horizon
URGN +81.14 pp
1Y Horizon
URGN +91.52 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ELTX Revenue | URGN Revenue | ELTX Op. Margin | URGN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -6842.2% | URGN |
| FY2019 | N/A | $0M | N/A | -608211.1% | URGN |
| FY2020 | $0M | $10M | -1919.2% | -1074.2% | URGN |
| FY2021 | $30M | $50M | -138.8% | -192.1% | ELTX |
| FY2022 | $0M | $60M | -1031.4% | -122.8% | URGN |
| FY2023 | N/A | $80M | N/A | -79.2% | URGN |
| FY2024 | N/A | $90M | N/A | -107.1% | URGN |
| FY2025 | N/A | $110M | N/A | -113.7% | URGN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ELTX
UNCLASSIFIED
Current IV
76.3%
IV Percentile
<1st %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ELTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
URGN
CONSOLIDATION
Current IV
109.4%
IV Percentile
10th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact URGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ELTX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
URGN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ELTX vs URGN Key Questions & Quantitative Answers
As of Nov 20, 2026, UroGen Pharma Ltd. (URGN) is the stronger overall head-to-head candidate over Elicio Therapeutics, Inc. (ELTX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ELTX carries a Unified Composite Score of 53.1/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin), whereas URGN carries 62.7/100 (BUY) at $27.65 (11.1x Forward P/E, -12.4% operating margin). Technical & Structure Timing Caution: ELTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.7); meanwhile URGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
URGN leads the Growth & Scale pillar: ELTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with URGN at +223.9% YoY revenue growth and +0.0% YoY earnings growth on $250M TTM revenue (91.4% gross margin, -12.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ELTX cumulative revenue shifted N/A while URGN shifted +1000.0%. In operating R&D and SG&A reinvestment, ELTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for URGN.
URGN screens cheaper on headline valuation multiples. ELTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas URGN trades at 11.1x Forward P/E, 14.6x Trailing P/E, N/M PEG, and 6.6x EV/Revenue (-52.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ELTX (-315.3% ROE) versus URGN (-1481.3% ROE) capital efficiency.
In options market volatility and institutional positioning, ELTX carries 76.3% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.41β · 92% Vol realized risk). By comparison, URGN carries 109.4% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.24β · 90% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
URGN vs ELTX · Reverse Pair
ELTX vs XLO
· Sector Peer
URGN vs ANAB
· Sector Peer
URGN vs RYTM
· Sector Peer
URGN vs REPL
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma